Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) EBT: 2022-2025

Historic EBT for Addex Therapeutics (ADXN) over the last 3 years, with Jun 2025 value amounting to -$892,296.

  • Addex Therapeutics' EBT rose 44.61% to -$892,296 in Q2 2025 from the same period last year, while for Jun 2025 it was -$4.7 million, marking a year-over-year decrease of 9.16%. This contributed to the annual value of -$5.6 million for FY2024, which is 100.46% down from last year.
  • According to the latest figures from Q2 2025, Addex Therapeutics' EBT is -$892,296, which was down 37.78% from -$647,610 recorded in Q1 2025.
  • Addex Therapeutics' 5-year EBT high stood at $6.6 million for Q4 2022, and its period low was -$7.5 million during Q2 2022.
  • For the 3-year period, Addex Therapeutics' EBT averaged around -$1.2 million, with its median value being -$952,337 (2023).
  • In the last 5 years, Addex Therapeutics' EBT spiked by 93.66% in 2023 and then tumbled by 119.12% in 2024.
  • Over the past 4 years, Addex Therapeutics' EBT (Quarterly) stood at $6.6 million in 2022, then crashed by 115.36% to -$1.0 million in 2023, then tumbled by 34.16% to -$1.4 million in 2024, then surged by 44.61% to -$892,296 in 2025.
  • Its EBT stands at -$892,296 for Q2 2025, versus -$647,610 for Q1 2025 and -$1.4 million for Q4 2024.